“GLP-1 drugs like Ozempic, Wegovy, and Zepbound work for weight loss.”
Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound) produce large average weight loss in eligible adults.
GLP-1 medicines work very well for weight loss in eligible adults, much better than diet and activity support alone. The useful question is whether a specific product's expected benefit and risks fit your health and goals, and whether you are ready to plan for long-term use.
Ask your prescriber what result is realistic for the exact medicine and dose, how side effects will be managed, and what the plan is if you stop.
Safety note: Nausea, diarrhea, vomiting and constipation are common. These medicines must not be used by anyone with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN 2). They can cause pancreatitis and gallbladder problems, low blood sugar is more likely when they are taken with insulin or sulfonylureas, and they should be stopped during pregnancy. Compounded and online versions are not FDA approved, and FDA has received reports of dosing errors with them, some needing hospital care.
Talk to a healthcare professional if: you are thinking about starting, stopping or changing one of these medicines, or you have side effects such as severe stomach pain or vomiting that will not stop.
Large randomized trials of about 2,000 and 2,500 adults found far more weight loss with obesity doses of semaglutide and tirzepatide than with placebo. Results differ by product, dose and person, and much of the lost weight comes back after stopping, so long-term treatment is often needed.
Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound) produce large average weight loss in eligible adults. In large trials, people on obesity doses lost about 15% to 21% of their body weight over 68 to 72 weeks, compared with 2% to 3% on placebo, alongside diet and activity support.
Semaglutide acts on the GLP-1 receptor, and tirzepatide acts on both the GIP and GLP-1 receptors. Wegovy and Zepbound are the brands approved for weight loss, and their labels say not to use them with other products that contain the same medicine or with other GLP-1 drugs. Weight regain is common after treatment stops, though some of the loss often lasts. A year after people in one semaglutide trial stopped treatment, they had regained about two-thirds of the weight they had lost but were still about 5.6% below their starting weight on average. In a tirzepatide trial, people switched to placebo after 36 weeks regained about 14% of their body weight over the next year, while those who stayed on it lost about 5.5% more. These are peptide medicines, but their trial results say nothing about other peptides sold online.
- Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al.; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183. PMID: 33567185
- Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al.; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216. DOI: 10.1056/NEJMoa2206038. PMID: 35658024
- Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF; STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564. DOI: 10.1111/dom.14725. PMID: 35441470. PMCID: PMC9542252
- Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, for subcutaneous use: US prescribing information. Revised 08/2026
- Novo Nordisk. WEGOVY (semaglutide) injection and tablets: US prescribing information. Revised 06/2026
- US Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Drug alerts and statements. Content current as of 10/01/2026